3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
15
Prostatic Neoplasms
10
Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Cardiovascular Diseases
3
Cardiotoxicity
3
Rectal Neoplasms
2
Polycystic Ovary Syndrome
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Kidney Neoplasms
2
Heart Failure
2
Head and Neck Neoplasms
2
Glioblastoma
2
Endometrial Hyperplasia
2
Carcinoma, Renal Cell
2
Waldenstrom Macroglobulinemia
1
Venous Thrombosis
1
Urogenital Neoplasms
1
Smoking
1
Interventions
Rituximab
295
Cyclophosphamide
240
Peripheral Blood Stem Cell Transplantation
114
fludarabine phosphate
110
Filgrastim
93
Etoposide
85
Radiotherapy
81
Lenalidomide
79
Vincristine
78
Prednisone
77
Mycophenolic Acid
66
Doxorubicin
61
Cyclosporine
59
Whole-Body Irradiation
58
Bendamustine Hydrochloride
58
Melphalan
57
Tacrolimus
53
Busulfan
51
fludarabine
50
Cytarabine
48
obinutuzumab
46
Methotrexate
45
Antilymphocyte Serum
43
Bortezomib
42
Methylprednisolone
37
Carmustine
37
sargramostim
36
ibritumomab tiuxetan
32
ibrutinib
30
Dexamethasone
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoma, Follicular
×
Atorvastatin
×
Clear all
NCT04904536
2025-04-10
STRONGER
The George Institute
Phase 3
Active not recruiting
190 enrolled